

CA27.29 TUMOR MARKER

EFFECTIVE NOVEMBER 21, 2018

CANCER ANTIGEN 27.29 TUMOR MARKER TESTING UPDATE

Effective November 21, 2018, Wisconsin Diagnostic Laboratories (WDL) is updating tumor marker testing by replacing CA27.29 with CA15-3. This change is part of a broader effort to increase the utilization of laboratory automation and to consolidate testing instrumentation, providing improved and consistent turnaround time for test results.

- Both tests measure the same tumor marker; however, results of the current and new test are not interchangeable since different testing instrumentation is used.

Parallel testing/Re-baselining: Patients who are routinely monitored by CA27.29 will undergo a “re-baselining” process in which the current (CA27.29) and new (CA15-3) tumor markers will be measured in parallel on the same sample.

- Over a six-month period beginning November 21, 2018, CA27.29 will be reported as a comment appended to all CA15-3 results.
- CA27.29 results (reported as a comment) can be interpreted as usual to assess tumor burden.
- CA15-3 results will serve as the new baseline for ongoing assessment of tumor burden.
- Parallel testing will be performed at no cost to the patient.
- Providers are encouraged to perform tumor marker testing on patients currently being monitored by CA27.29 within the six-month period from November 21, 2018 to May 21, 2019.
- **Reporting of test results will be delayed by approximately two hours during this six-month re-baselining period.**

Summary:

Current Test	New Test	Transition Period	Comment
CA27.29	CA15-3	6 months, beginning November 21, 2018	CA15-3 will replace CA27.29. Both tests measure the same tumor marker but results are not interchangeable.

For Technical Questions or Additional Information, Please Call:

- Ian Gunsolus, PhD, Associate Director of Clinical Chemistry and Toxicology, 414.805.6972, igunsolus@mcw.edu